

Cell Metabolism, Volume 8


**Supplemental Data**

**Ablation of CD11c-Positive Cells**

**Normalizes Insulin Sensitivity**


**in Obese Insulin Resistant Animals**

David Patsouris, Ping-Ping Li, Divya Thapar, Justin Chapman, Jerrold M. Olefsky, and Jaap G. Neels




**Figure S1. CD11c-DTR Conditional Cell Ablation System**

Illustrations depicting the experimental strategies used in this study. **A**) Illustrates the diphtheria toxin (DT) mediated conditional cell ablation system. To convey DT sensitivity specifically to CD11c expressing cells, the simian DT receptor (DTR) is expressed as a transgene in normally DT-insensitive mice as a GFP fusion protein under control of the mouse CD11c promoter. The cytotoxicity of the heterodimeric DT is strictly dependent on receptor-mediated endocytosis. Upon administration, DT enters the CD11c<sup>+</sup> cells via interaction of its DT B subunit with the simian DTR. Upon endocytosis, the DT A subunit is released and catalyzes ADP-ribosylation of elongation factor 2, resulting in inhibition of protein synthesis. As a consequence, DT induces rapid apoptosis in both mitotic and terminally differentiated CD11c<sup>+</sup> cells. **B**) Depicts the bone marrow transplant (BMT) strategy and timeline followed. Bone marrow (BM) from both transgenic CD11c-DTR and wild-type (WT) donor mice is transplanted through the tail vein in WT recipient mice that received a lethal dose of irradiation to deplete their endogenous BM. The transplanted mice were allowed to recover for 6 weeks and reconstitute their BM before they were started on either a normal chow or high fat diet (HFD) for a period of 16 weeks. After this period, DT treatment commenced and the mice underwent metabolic testing at different stages of treatment.




**Figure S2. Mice Weights during DT Treatment**

Mice were injected ip with DT every other day over a 9-day period, with jugular catheters implanted on day 4, and euglycemic clamp studies performed on day 7. Mice weights were followed during this 9-day period. Data are expressed as mean  $\pm$  SEM. ns indicates no significant differences in weight between WT and CD11c-DTR BMT mice.  $n=5$  per group.



**Figure S3: Ob/Ob Data**

Genetically obese leptin-deficient Ob/Ob mice were transplanted with WT or CD11c-DTR bone marrow and underwent an **a**) insulin tolerance test (ITT) after 1 day of DT treatment and **b**) a glucose tolerance test after 4 days DT treatment. The adipose tissue macrophage content of these animals was measured by quantifying the relative mRNA expression of the macrophage markers **c**) F4/80, **d**) CD11b, **e**) CCR2, and **f**) CD11c. Data are expressed as mean  $\pm$  SEM. \* $P < 0.05$  and \*\* $P < 0.01$  compared to WT BMT;  $n = 6$ .



**Figure S4: Raw Clamp Data**

*In vivo* liver and adipose tissue insulin sensitivity as determined by euglycemic clamp studies in NC- and HFD-fed WT and CD11c-DTR BMT mice treated with DT. **a)** Hepatic glucose production under basal (non insulin-stimulated) and clamp (insulin-stimulated) conditions. Insulin-stimulated reduction of hepatic glucose production reflects liver insulin sensitivity. **b)** Fasted plasma FFA levels under basal (non insulin-stimulated) and clamp (insulin-stimulated) conditions. Insulin-stimulated reduction of plasma FFA levels reflects adipose insulin sensitivity. NC data was from mice treated with DT for 14 days. HFD data was combined from 3 sets of mice that received DT for 1, 3, or 7 days. Data are expressed as mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\*  $P < 0.001$ . ns means not significant.  $n = 5$  per group for NC data and  $n \geq 15$  per group for HFD data.